Systimmune has a unified set of key technology platforms that enable the advancement of product candidates in all four of its technology chains. It has developed more than ten cutting-edge drug product development lines with its successful operations. The current platforms can produce monoclonal antibodies, bi-specific antibodies, multi-specific antibodies, ADC, and fusion proteins. Furthermore, the company is innovating new technology platforms at the forefront of drug sciences to expand its range of therapeutic modalities. By 2022, the company had applied for approximately 200 patents in 16 different countries or regions across the globe. They have been granted 67 patents for their inventions both domestically and internationally.